Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD147 antibody specifically and effectively inhibits infection and cytokine storm of SARS-CoV-2 and its variants delta, alpha, beta, and gamma.
Geng J, Chen L, Yuan Y, Wang K, Wang Y, Qin C, Wu G, Chen R, Zhang Z, Wei D, Du P, Zhang J, Lin P, Zhang K, Deng Y, Xu K, Liu J, Sun X, Guo T, Yang X, Wu J, Jiang J, Li L, Zhang K, Wang Z, Zhang J, Yan Q, Zhu H, Zheng Z, Miao J, Fu X, Yang F, Chen X, Tang H, Zhang Y, Shi Y, Zhu Y, Pei Z, Huo F, Liang X, Wang Y, Wang Q, Xie W, Li Y, Shi M, Bian H, Zhu P, Chen ZN. Geng J, et al. Among authors: xu k. Signal Transduct Target Ther. 2021 Sep 25;6(1):347. doi: 10.1038/s41392-021-00760-8. Signal Transduct Target Ther. 2021. PMID: 34564690 Free PMC article.
An engineered bispecific human monoclonal antibody against SARS-CoV-2.
Li Z, Li S, Zhang G, Peng W, Chang Z, Zhang X, Fan Z, Chai Y, Wang F, Zhao X, Li D, Zhang R, He Z, Zou W, Xu K, Lei W, Liu P, Hao J, Zhang J, Sun L, Wu G, Tan S, Gao GF, Gao F, Wu Y. Li Z, et al. Among authors: xu k. Nat Immunol. 2022 Mar;23(3):423-430. doi: 10.1038/s41590-022-01138-w. Epub 2022 Feb 28. Nat Immunol. 2022. PMID: 35228696
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. Xu K, et al. Cell. 2022 Jun 23;185(13):2265-2278.e14. doi: 10.1016/j.cell.2022.04.029. Epub 2022 Apr 27. Cell. 2022. PMID: 35568034 Free PMC article.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: xu k. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J, Han ZB, Liang Y, Zhang XF, Jin YQ, Du LF, Shao S, Wang H, Hou JW, Xu K, Lei W, Lei ZH, Liu ZM, Zhang J, Hou YN, Liu N, Shen FJ, Wu JJ, Zheng X, Li XY, Li X, Huang WJ, Wu GZ, Su JG, Li QM. Zhang J, et al. Among authors: xu k. Elife. 2022 Aug 25;11:e78633. doi: 10.7554/eLife.78633. Elife. 2022. PMID: 36004719 Free PMC article.
11,535 results
You have reached the last available page of results. Please see the User Guide for more information.